Chester County News and Community Website
CHESTERBROOK, PA — Biopharmaceutical company Trevena, Inc. (Nasdaq: TRVN), known for its innovative work in developing and commercializing novel medicines for central nervous system disorders, recently announced the acceptance of …
Trevena’s Investigator-Led RELIEVE Study Accepted for Presentation at 2024 American Burn Association Meeting Read More
BERWYN, PA — Chester County-based biopharmaceutical company Annovis Bio, Inc. (NYSE: ANVS) announced this week that its phase II/III study of buntanetap, a potential treatment for Alzheimer’s Disease (AD), has …
Annovis Bio’s Phase II/III Study of Buntanetap Exceeds Full Enrollment Read More
RADNOR, PA — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a leading pharmaceutical company, has announced that it will present seven abstracts at the upcoming American Epilepsy Society (AES) 2023 Annual Meeting. …
Marinus Pharmaceuticals Takes Center Stage at AES 2023 with Seven Presentations and Scientific Exhibit Read More
PHILADELPHIA, PA — Imvax, Inc., a clinical-stage biotechnology company, recently announced details of its two poster presentations at the 2023 Society for NeuroOncology (SNO) 28th Annual Meeting. The event was …
Imvax Presents Promising Results from IGV-001 Phase 1b Study for Glioblastoma at SNO Annual Meeting Read More
WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) this week announced disappointing top-line results from a Phase 2b study of zunsemetinib (ATI-450) in patients with moderate to severe rheumatoid arthritis …
Aclaris Therapeutics Halts Development of Rheumatoid Arthritis Drug After Phase 2b Study Misses Primary Endpoint Read More
MALVERN, PA — Biopharmaceutical company Ocugen, Inc. (NASDAQ: OCGN) has announced the commencement of its Phase 1/2 GARDian clinical trial for OCU410ST (AAV5-hRORA), a gene therapy candidate being developed to …
Ocugen Initiates Phase 1/2 GARDian Clinical Trial for Stargardt Disease Therapy Read More
JENKINTOWN, PA — SFA Therapeutics recently announced the completion of a bridge financing of $4.5 million, led by North South Ventures. Additional participants in this raise were the Ben Franklin …
SFA Therapeutics Announces Updated Psoriasis Data for SFA-002, Bridge Financing, and Foundational Patent Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a frontrunner in the world of biopharmaceuticals, recently disclosed its Q3 2023 financial results and a business update that holds promising news for …
Ocugen’s Promising Advancements: Q3 2023 Financial Results and Progress in Ophthalmic Gene Therapies, Regenerative Cell Therapies, and Vaccines Portfolio Read More
BERWYN, PA — Mural Health, a company specializing in patient-first clinical trial technology, is spearheading an initiative to improve access to experimental treatments for millions of Americans on public assistance. …
Mural Health Advocates for Income Exclusion to Boost Clinical Trial Diversity and Access Read More
NEWTOWN, PA — Helius Medical Technologies, Inc. (Nasdaq: HSDT) this week announced the publication of a white paper demonstrating that rehabilitative treatment with the Portable Neuromodulation Stimulator (“PoNS®”) can drastically improve return-to-work …
Helius Medical Technologies, Inc. Announces Study Results Demonstrating That PoNS Therapy Helps Patients with Traumatic Brain Injury Return to Work Read More